Medicare announces lower prices on 10 common, high-cost drugs

by 8DonCo Thu Aug 15, 2024 9:20 pm

Here are the negotiated prices for the drugs, based on a 30-day supply:

Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price.
Xarelto, a blood thinner from Johnson & Johnson: $197 negotiated price, down from $517 list price.
Januvia, a diabetes drug from Merck: $113 negotiated price, down from $527 list price.
Jardiance, a diabetes drug from Boehringer Ingelheim and Eli Lilly: $197 negotiated price, down from $573 list price.
Enbrel, a rheumatoid arthritis drug from Amgen: $2,355 negotiated price, down from $7,106 list price.
Imbruvica, a drug for blood cancers from AbbVie and Johnson & Johnson: $9,319 negotiated price, down from $14,934 list price.
Farxiga, a drug for diabetes, heart failure and chronic kidney disease from AstraZeneca: $178 negotiated price, down from $556 list price.
Entresto, a heart failure drug from Novartis: $295 negotiated price, down from $628 list price.
Stelara, a drug for psoriasis and Crohn’s disease from J&J: $4,695 negotiated price, down from $13,836 list price.
Fiasp and NovoLog, diabetes drugs from Novo Nordisk: $119 negotiated price, down from $495 list price.